Brought to you by www.DealSearchOnline.com
December 17, 2012 Issue:
Recent Health Care M&A Deals
Big Pharma And M&A –
Will The Big Deals Become A Thing Of The Past
Spotlight on: Medical Devices
Webcast Calendar
Recent Health Care M&A Deals
BIOTECHNOLOGY
Acquirer
Target
Price
Amgen
deCode Genetics
$415 million
Gilead Sciences
YM BioSciences Inc.
$510 million
E-HEALTH
Acquirer
Target
Price
Sutherland Global Services
Apollo Health Street Limited
$184.1 million
PHARMACEUTICALS
Acquirer
Target
Price
Pernix Therapeutics Holdings, Inc.
Somaxon Pharmaceuticals, Inc.
$25 million
OTHER
Acquirer
Target
Price
BioScrip
HomeChoice Partners, Inc.
$70 million
NEW- The Health Care Services Acquisition Report, 19th Edition – Preorder Today!
Deals have been made. The 2013 Health Care Services Acquisition Report contains private deals in this market that are frequently too small to make into financial press. Take advantage of our limited 2-for-1 offer – preorder The 2013 Health Care Services Acquisition Report by December 31st and receive The 2012 Health Care Services Acquisition Report FREE ($595 value)! Now that’s a recession resistant deal. Go to http://www.levinassociates.com/hardescription or call 800-248-1668 to preorder today!
Big Pharma And M&A –
Will The Big Deals Become A Thing Of The Past
With all the talk of health care reform, or “ObamaCare,” moving forward as a result of both the Supreme Court decision last June and President Obama’s reelection last month, we thought it might be worthwhile to take a look at the pharmaceutical M&A market going forward and what impact these “reforms” will have on transaction size, frequency and structure…..Read more
AVAILABLE NOW – New Sector M&A Reports!
Our team of experts at The Health Care M&A Information Source has been working around the clock to bring you the inside scoop on the latest in the health care M&A market. Our newest M&A reports are loaded with crucial transaction information, current and historic, to help you make smart investment decisions in these health care sectors: Biotechnology; Home Health and Hospice; Hospital; Managed Care; Medical Device; Not-for-Profit Health Care; and Pharmaceutical. http://www.levinassociates.com/shoppingcartnew/113
Spotlight on: Medical Devices
Vessix Vascular, Inc.’s breakthrough device, an easy-to-use renal denervation system that treats uncontrolled hypertension, made it a natural acquisition target for Boston Scientific Corp. (NYSE: BSX). Boston Scientific develops and manufactures minimally invasive medical devices used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, among others…Read more
Conference Calendar…Click here to see more
